Today, EGFR inhibitors, either small inhibitory molecules (e.g., erlotinib, gefitinib, or lapatinib) or inhibitory antibodies (e.g., cetuximab or panitumumab) are approved for the treatment of non–small cell lung cancer, pancreatic cancer, breast cancer, colorectal carcinoma, and squamous cell carcinoma of head and neck (8, 9). This evidence concerns the gene EGFR and breast carcinoma.